Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2025-12-24 @ 7:59 PM
Ignite Modification Date:
2025-12-24 @ 7:59 PM
NCT ID:
NCT03807804
Brief Summary:
The primary object of this clinical study is to investigate the efficacy of HLCM051 in patients with ARDS caused by pneumonitis.
Detailed Description:
The objectives of this clinical study are as follows(ARDS caused by pneumonia cohort):
1. Primary objective To investigate the efficacy of HLCM051 in patients with ARDS caused by pneumonia
2. Secondary objective To confirm the safety of HLCM05 in patients with ARDS caused by pneumonia
3. Exploratory objective To investigate changes of biomarkers in patients with ARDS caused by pneumonia
The number of patients enrolled is 30 (20 patient in the HLCM051 group and 10 patients in the standard therapy group)
The objectives of this clinical study is as follows(ARDS caused by COVID-19 cohort):
1\. Exploratory objective To investigate the safety and the efficacy of HLCM051 in patients with ARDS caused by SARS-Cov-2 infection
The number of patients enrolled is Approximately 5 (the HLCM051 group only)
Study:
NCT03807804
Study Brief:
Protocol Section:
NCT03807804